Two more funds have doubled their performance, bringing the total number of "doubling funds" to four this year.

Innovative drug sector exploded, related funds performance increased. As of July 17th, China Merchants Hong Kong Stock Connect Medical A, Yongyuan Medical Innovation Select A net unit value has increased by over 100% this year, ranking as the third and fourth "doubling funds" of the year. The interviewed fund managers stated that they are optimistic about the prospects of the innovative drug sector in the mid-term. For the vast majority of Chinese innovative drug companies, whether they can enter the largest market space in the pharmaceutical industry in Europe and America will be the key to determining their future success or failure.